Legend Biotech (LEGN) EBITDA Margin (2019 - 2025)
Legend Biotech (LEGN) posted EBITDA Margin of 6.43% for Q4 2025, down 143.18% quarter-over-quarter from 14.9% in Q3 2025, and up 3609.0% year-on-year from 0.17% in Q4 2024.
Legend Biotech (LEGN) EBITDA Margin (2019 - 2025) Analysis & Trends
Legend Biotech (LEGN) has reported EBITDA Margin for 7 consecutive years, with 6.43% the latest figure, recorded in Q4 2025.
- EBITDA Margin for Q4 2025 came in at 6.43%, up 3609.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 8.05% (up 1365.0% YoY), and the FY2025 annual result was 13.27%, up 3607.0% from the prior year.
- EBITDA Margin was 6.43% for Q4 2025 at Legend Biotech, down from 14.9% in the prior quarter.
- Over five years, EBITDA Margin peaked at 395.35% in Q4 2022 and troughed at 1150.03% in Q3 2022.
- Average EBITDA Margin over 5 years is 131.28%, with a median of 2.54% recorded in 2022.
- Year-over-year, EBITDA Margin plunged 137590 bps in 2021 and jumped 106416 bps in 2023.
- Over 5 years, EBITDA Margin stood at 230.36% in 2021, then surged by 72 bps to 395.35% in 2022, then tumbled by 85 bps to 57.62% in 2023, then sank by 174 bps to 42.52% in 2024, then soared by 85 bps to 6.43% in 2025.
- Per Business Quant data, the three most recent EBITDA Margin figures were 6.43% in Q4 2025, 14.9% in Q3 2025, and 0.46% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Genmab A | 276,399.99 Bn | 276,398.47 Bn | 831.00 Mn | -11.83% |
| 2 | Akari Therapeutics | 1,217.26 Bn | 1,217.26 Bn | - | - |
| 3 | BeOne Medicines | 419.38 Bn | 414.59 Bn | 1.35 Bn | 16.51% |
| 4 | Vertex Pharmaceuticals | 126.54 Bn | 119.30 Bn | 2.59 Bn | 38.10% |
| 5 | Pharming | 110.17 Bn | 110.12 Bn | 65.80 Mn | -6.78% |
| 6 | Regeneron Pharmaceuticals | 64.97 Bn | 56.22 Bn | 3.31 Bn | 18.35% |
| 7 | Argenx Se | 56.44 Bn | 56.44 Bn | 1.18 Bn | 30.35% |
| 8 | Alnylam Pharmaceuticals | 40.09 Bn | 37.08 Bn | 959.66 Mn | 17.24% |
| 9 | Revolution Medicines | 37.15 Bn | 37.15 Bn | - | - |
| 10 | Legend Biotech | 11.04 Bn | 10.14 Bn | 242.10 Mn | -6.43% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -6.43% |
| Sep 30, 2025 | 14.90% |
| Jun 30, 2025 | 0.46% |
| Mar 31, 2025 | 31.13% |
| Dec 31, 2024 | -42.52% |
| Sep 30, 2024 | 39.59% |
| Jun 30, 2024 | 15.40% |
| Mar 31, 2024 | -51.06% |
| Dec 31, 2023 | 57.62% |
| Sep 30, 2023 | -85.87% |
| Jun 30, 2023 | -281.06% |
| Mar 31, 2023 | -271.34% |
| Dec 31, 2022 | 395.35% |
| Sep 30, 2022 | -1,150.03% |
| Jun 30, 2022 | 25.22% |
| Mar 31, 2022 | 4.62% |
| Dec 31, 2021 | 230.36% |
| Sep 30, 2021 | -726.03% |
| Jun 30, 2021 | -857.64% |
| Mar 31, 2021 | 31.79% |